Cochlear’s ASX Update Puts Growth Strategy in Focus as Shares Retreat

Highlights

• Cochlear maintained its profit forecast and reported trading consistent with expectations.
• Expanding adult access to implants remains central to its growth strategy.
• Technology investment and stronger referral networks underpin plans to improve efficiency.

Forecast Holds Despite Share Decline

Cochlear Limited (ASX: COH) traded at a current market price of AU$150.79, declining 1.4%, following its announcement on 13 November 2026. The hearing implant manufacturer retained its financial outlook while presenting initiatives to expand treatment access at its Capital Markets Day.

According to the announcement, FY27 underlying net profit is forecast at AU$330 million to AU$350 million, accompanied by low single-digit revenue growth in constant currency. Management left the assumptions supporting its earlier guidance unchanged.

Trading through October remained consistent with internal expectations. According to the announcement, developed-market cochlear implant volumes grew at a mid-single-digit rate. Revenue in these markets is expected to increase modestly as referral programmes and direct consumer outreach support demand.

Adult Treatment Gap Offers Potential

According to the announcement, fewer than 5% of adults who could benefit from an implant have received one. Cochlear sees improving adoption across developed markets as its strongest long-term expansion opportunity.

Its approach centres on clearer professional referral routes, product innovation and simpler care delivery. Helping patients move more easily from initial assessment towards surgery could create a steadier flow of procedures.

According to the presentation, the US Cochlear-supported channel achieved 10% growth in FY26. UK referrals doubled between FY23 and FY26, while Australian private surgeries increased 15% in FY26.

Investment Builds Operational Capacity

According to the presentation, Cochlear invested AU$323 million in research and development during FY26, with spending since FY00 exceeding AU$3 billion.

The company has substantially completed its core technology transformation. Management expects the upgraded infrastructure, digital services and connected care capabilities to improve productivity and support expansion.

Management Change and Outlook

According to the announcement, North America President Lisa Aubert will leave later this year after 32 years of service. Recruitment for her successor is underway.

Management’s longer-term ambition is approximately 10% annual underlying net profit growth, according to the announcement. Progress will depend on stronger treatment referrals, broader adoption and efficiency gains. Converting these opportunities into consistent earnings remains the execution test.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au